Cy­tomX halts lead pro­gram and will seek a part­ner as breast can­cer drug dis­ap­points

Mixed Phase II re­sults are forc­ing Cy­tomX to slam the brakes on one of its lead can­cer drugs — un­less it can con­vince a part­ner to help take it fur­ther.

The da­ta come from a study of praluzatam­ab rav­tan­sine, Cy­tomX’s take on a CD166-tar­get­ing an­ti­body-drug con­ju­gate, in breast can­cer that com­prised three sep­a­rate arms: Arm A fo­cused on hor­mone re­cep­tor-pos­i­tive, HER2-non-am­pli­fied pa­tients; Arm B and C both re­cruit­ed pa­tients with triple-neg­a­tive breast can­cer, but the for­mer test­ed the drug as a monother­a­py and Arm C gave it in com­bi­na­tion with an in-house an­ti-PD-L1 drug dubbed pacmil­imab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER